Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 04, 2022

Prognostic Value of Tumour Mutational Burden in Patients With Resected Stage I and II Lung Adenocarcinomas

Lung Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort
Lung Cancer 2022 Dec 01;174(xx)27-35, L Bubendorf, M Zoche, U Dafni, et al

Further Reading